Insider Buying: MBX Biosciences, Inc. (NYSE:MBX) Director Buys 47,502 Shares of Stock

MBX Biosciences, Inc. (NYSE:MBX) Director Carl L. Gordon purchased 47,502 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was acquired at an average price of $9.87 per share, for a total transaction of $468,844.74. Following the purchase, the director now owns 3,205,930 shares of the company’s stock, valued at approximately $31,642,529.10. This represents a 1.50 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

MBX Biosciences Trading Up 2.9 %

Shares of MBX opened at $11.22 on Thursday. The firm has a 50 day simple moving average of $14.22. MBX Biosciences, Inc. has a 52-week low of $8.63 and a 52-week high of $27.50.

Institutional Trading of MBX Biosciences

Institutional investors have recently added to or reduced their stakes in the stock. Teachers Retirement System of The State of Kentucky acquired a new stake in MBX Biosciences in the third quarter valued at $694,000. Barclays PLC bought a new stake in MBX Biosciences in the third quarter valued at about $426,000. NEA Management Company LLC acquired a new stake in MBX Biosciences during the third quarter valued at approximately $93,904,000. Geode Capital Management LLC acquired a new stake in MBX Biosciences during the third quarter valued at approximately $579,000. Finally, The Manufacturers Life Insurance Company bought a new position in MBX Biosciences during the 3rd quarter worth approximately $1,200,000.

MBX Biosciences Company Profile

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.